PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View

This article was originally published on Nasdaq

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 26 cents in second-quarter 2023, narrower than the year-ago loss and the Zacks Consensus Estimate of a loss of 34 cen